What can be learned from the experience with the fixed low-dose combination of perindopril/indapamide in the treatment of hypertension?

Bibliography

• MARQUES-VIDAL P, TUOMILEHTO J: awareness, treatment andcontrol in the community: is the 'rule of' still valid ?j Hum. Hypertens. (1997) 11:213–223.
   Google Scholar
• STAESSEN JA, WANG J, BIANCHI G, WH: Essential hypertension. Lancet (2003) 361:1629–1641.
   PubMed Web of Science ®Google Scholar
• •This paper reviews all aspects of essential hypertension, including pathophysiological mechanisms and therapeutic concepts.
   Google Scholar
• DICKERSON CJ, HINGORANI AD, MJ, PALMER CR, BROWN MJ:Optimisation of antihypertensive treatment crossover rotation of four major classes. Lancet (1999) 353:2008–2013.
   PubMed Web of Science ®Google Scholar
• 2003 EUROPEAN SOCIETY OF HYPERTENSION: European Society of Cardiology guidelines for the management of arterial hypertension. J. Hypertens. (2003) 21:1011–1053.
   Google Scholar
• ••The European guidelines propose toInitiate antihypertensive therapy with either a monotherapy or a low-dose combination therapy. This is the first time that combination therapy is considered officially as a first-line option.
   Google Scholar
• CHOBANIAN AV, BAKRIS GL, BLACK HR et al.: Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension (2003) 42:1206–1252.
   PubMed Web of Science ®Google Scholar
• ••According to experts in the US, one shouldstart antihypertensive therapy whenever possible with a diuretic. Combination therapy may, however, be used to initiate therapy in patients with systolic pressure 160 mmHg and/or diastolic pressure 100 mmHg.
   Google Scholar
• NEUTEL JM, SMITH DH, WEBER MA: Low-dose combination therapy: an important first-line treatment in the management of hypertension. Am. J. Hypertens. (2001) 14:286–292.
   PubMed Web of Science ®Google Scholar
• WAEBER B: Very-low-dose combination: a first-line choice for the treatment of hypertension? Hypertens. (2003) 21\(Suppl. 3):S3–S10.
   Google Scholar
• ••This paper reviews the rationale ofcombination therapy in the management of hypertension.
   Google Scholar
• LAW MR, WALD NJ, MORRIS JK, JORDAN RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. Br. Med. J. (2003) 326:1427.
   PubMed Web of Science ®Google Scholar
• ••This meta-analysis of placebo-controlledtrials shows that most antihypertensive agents have a dose-dependent increase in the incidence of side-effects and that it may be preferable, in order to preserve tolerability, to combine two medications at low doses.
   Google Scholar
• LAURENT S: Very-low-dose combinationof perindopril and indapamide: efficacy on blood pressure and target-organ damage. Hypertens. (2003) 21\(Suppl. 3):11–18.
   Google Scholar
• MYERS MG, ASMAR R, LEENEN FH, SAFAR M: Fixed low-dose combination therapy in hypertension-a dose response of perindopril and indapamide.. (2000) 18:317-325. This was one of the key studies on which the development of the Per/Ind combination was based.
   Google Scholar
• CHALMERS J, CASTAIGNE A, T, CHASTANG C: Long-term efficacy of a new, fixed, very-low-dose angiotensin-converting enzyme-inhibitor/ diuretic combination as first-line therapy in elderly hypertensive patients. J. Hypertens. (2000) 18:327–337.
   PubMed Web of Science ®Google Scholar
• •First description of the long-term antihypertensive efficacy and tolerability versus placebo of a fixed low-dose combination given as first-line therapy in elderly hypertensive patients.
   Google Scholar
• ASMAR RG, LONDON GM, O'ROURKE ME, SAFAR ME: Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopriYindapamide combination in hypertensive patient: a comparison with atenolol. Hypertension (2001) 38:922–926.
   PubMed Web of Science ®Google Scholar
• FRANKLIN SS, LARSON MG, SA et al.: Does the relation of blood pressure to coronary heart disease risk change with aging? The Framingham Heart Study. Circulation (2001) 103:1245–1249.
   PubMed Web of Science ®Google Scholar
• •Report of the observations made in the Framingham Heart Study showing the importance of systolic and pulse pressure as a determinant of cardiovascular risk.
   Google Scholar
• SWALES JD: Current clinical practice in hypertension: the EISBERG (Evaluation and Interventions for Systolic Blood pressure Elevation-Regional and Global) project. Am. Heart J. (1999) 138:231–237.
   PubMed Web of Science ®Google Scholar
• LLOYD-JONES DM, EVANS JC, LARSON MG, O'DONNELL CJ, LEVY D: Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension (1999) 34:381–385.
   Google Scholar
• LONDON GM, ASMAR RG, O'ROURKE ME SAFAR ME: Mechanism(s) of selective systolic blood pressure reduction after a low-dose combination of perindopriYindapamide in hypertensive subjects: comparison with atenolol. J. Am. Coll. Cardiol (2004) 43:92–99.
   PubMed Web of Science ®Google Scholar
• CHANUDET X, CHAMP VALLINS M: efficacy and tolerability of -dose perindopril/indapamide combination compared with losartan in the treatment of essential hypertension. Int. .1. (2001) 55:233–239.
   Google Scholar
• MORGAN T, ANDERSON A: Low-dose combination therapy with perindopril and indapamide compared with irbesartan. Drug Invest. (2002) 22:553–560.
   Google Scholar
• BRUNNER HR, MENARD J, B et al: Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J. Hypertens. (1990) 8:3–11.
   PubMed Web of Science ®Google Scholar
• •This paper reviews the advantages and the shortcomings of the different therapeutic strategies in the field of hypertension.
   Google Scholar
• MOURAD JJ, WAEBER B, ZANNAD F, LAVILLE M, DURU G, ANDREJAK M: Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopriYindapamide versus a sequential monotherapy or a stepped-care approach. ./. Hypertens. (2004) 22:2379–2386.
   PubMed Web of Science ®Google Scholar
• ••This is an original trial comparingdifferent therapeutic strategies, including a fixed low-dose combination as first-line therapy, rather than different antihypertensive medications.
   Google Scholar
• NEAL B, MACMAHON S: An overview of 37 randomised trials of blood pressure lowering agents among 270,000 individuals. World Health Organization-International Society of Hypertension Blood Pressure Lowering Treatment Trialists' Collaboration. Clin. Exper. Hypertens. (1999) 21:517–529.
   Google Scholar
• MIMRAN A, RIBSTEIN J: therapy in renal disease and transplantation. J. Hypertens. (1992) 10\(Suppl. 5):79–85.
   Google Scholar
• LEWINGTON S, CLARKE R, QIZILBASH N, PETO R, COLLINS R: Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet (2002) 360: 1903-1913.
   Google Scholar
• STAESSEN JA, GASOWSKI J, WANG JG et al: Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet (2000) 355:865–872.
   PubMed Web of Science ®Google Scholar
• •Meta-analysis showing the benefits of antihypertensive treatment in elderly patients with isolated systolic hypertension.
   Google Scholar
• DAHLOF B, DEVEREUX RB, KJELDSEN SE et al: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet (2002) 359:995–1003.
   PubMed Web of Science ®Google Scholar
• PEPINE CJ, HANDBERG EM, COOPER-DEHOFF RM et al: A calcium antagonist versus a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. "AMA (2003) 290:2805–2816.
   Google Scholar
• LEWIS EJ, HUNSICKER LG, WR et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to Type 2 diabetes. N Engl. J. Med. (2001) 345:851–860.
   PubMed Web of Science ®Google Scholar
• BRENNER BM, COOPER ME, DE ZEEUW D et al: Effects of losartan on renal and cardiovascular outcomes in patients with Type 2 diabetes and nephropathy. N Engl. J. Med. (2001) 345:861–869.
   PubMed Web of Science ®Google Scholar
• PARVING HH, LEHNERT H, BROCHNER-MORTENSEN J, R, ANDERSEN S, ARNER P: The effect of irbesartan on the development diabetic nephropathy in patients with Type 2 diabetes. N Engl. J. Med. (2001) 345:870–878.
   PubMed Web of Science ®Google Scholar
• FLEISCHMANN EH, SCHMIEDER RE: Are all antihypertensive drug classes equal in reducing left ventricular hypertrophy? Curr. Cardiol Rep. (2002) 4:474–478.
   PubMedGoogle Scholar
• •Meta-analysis describing the impact of different classes of antihypertensive agents on the regression of cardiac hypertrophy.
   Google Scholar
• MASCHIO G, MARCANTONI C, BERNICH P: Lessons from large interventional trials on antihypertensive therapy in chronic renal disease. Nephrol Dial. Transplant (2002) 17\(Suppl. 11):47–49.
   Google Scholar
• •This paper reviews the effects of antihypertensive therapy in hypertensive patients with chronic renal disease. The rationale for the use of blockers of the renin-angiotensin system is extensively discussed.
   Google Scholar
• MOGENSEN CE, VIBERTI G, HALIMI S et al.: Effect of low-dose perindopriYindapamide on albuminuria in diabetes: preteraz in albuminuria regression: PREMIER. Hypertension (2003) 41:1063–1071.
   PubMed Web of Science ®Google Scholar
• ••Controlled trial demonstrating thesuperiority of the low-dose Per/hid combination compared with enalapril in regressing albuminuria ofhypertensive patients with Type 2 diabetes.
   Google Scholar
• DE LUCA N, MALLION JM, O'ROURKE ME et al.: Regression of left ventricular mass in hypertensive patients teated with perindopriliindapamide as a first-line combination: the REASON echocardiography study. Am. J. Hypertens. (2004) 17:660–667.
   Google Scholar
• ••Controlled trial showing that the low-dosePer/Ind combination is more effective than I3-adrenoceptor blockade with atenolol monotherapy in regressing cardiac hypertrophy of hypertensive patients.
   Google Scholar
• DAHLOF B, GOSSE P, GUERET P: On behalf of the PICXEL investigators. (accepted for publication J. Hypertension).
   Google Scholar
• ••Controlled trial demonstrating that thelow-dose Per/Ind combination is more effective than ACE inhibition monotherapy with enalapril in regressing cardiac hypertrophy of hypertensive patients.
   Google Scholar